<i>In Vivo</i> E2F Reporting Reveals Efficacious Schedules of MEK1/2–CDK4/6 Targeting and mTOR–S6 Resistance Mechanisms
Jessica L.F. Teh(Thomas Jefferson University), Andrew E. Aplin(Thomas Jefferson University)
Cited by 77
Related Papers
Mutant BRAF and MEK Inhibitors Regulate the Tumor Immune Microenvironment via Pyroptosis
|Cancer Discovery|2019|482
Akt3-Mediated Resistance to Apoptosis in B-RAF–Targeted Melanoma Cells
|Cancer Research|2010|194
Targeting SOX10-deficient cells to reduce the dormant-invasive phenotype state in melanoma
|Nature Communications|2022|98
BH3-only protein silencing contributes to acquired resistance to PLX4720 in human melanoma
|Cell Death and Differentiation|2012|69
Fibroblast-derived Neuregulin 1 Promotes Compensatory ErbB3 Receptor Signaling in Mutant BRAF Melanoma
|Journal of Biological Chemistry|2015|69